How to Safely Stop Dayvigo (Lemborexant): A Clinician-Guided Discontinuation Protocol

Why Lemborexant Is Different from Older Sleep Drugs

Lemborexant works by blocking orexin-A and orexin-B receptors (OX1R and OX2R) in the lateral hypothalamus, reducing the wake-promoting signal rather than broadly suppressing the central nervous system [1]. This mechanism matters when you stop the drug. Benzodiazepines and Z-drugs (zolpidem, eszopiclone) enhance GABAergic inhibition across the brain, and chronic GABA-A receptor modulation leads to receptor downregulation, tolerance, and a well-documented withdrawal syndrome [2]. Orexin receptor blockade does not produce the same neuroadaptive changes.

The SUNRISE-1 trial (N=1,006) randomized adults aged 55 and older to lemborexant 5 mg, 10 mg, or placebo and assessed objective sleep parameters via polysomnography over 30 nights [1]. At the end of the treatment period, abrupt discontinuation did not produce statistically significant rebound insomnia on the first or second night off drug. Wake-after-sleep-onset (WASO) returned to near-baseline values rather than overshooting them. That pattern is the pharmacological signature of low physical dependence.

The Endocrine Society and the American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline on chronic insomnia pharmacotherapy notes that DORAs demonstrate a "more favorable discontinuation profile" than benzodiazepine receptor agonists, though long-term data beyond 12 months remain limited [3].

How Lemborexant Works (and Why That Shapes Discontinuation)

Understanding the orexin system clarifies why stopping Dayvigo is generally straightforward. Orexin-producing neurons are a small cluster of roughly 70,000 cells in the human lateral hypothalamus [4]. They project widely to wake-promoting nuclei (locus coeruleus, tuberomammillary nucleus, dorsal raphe) and act as a master switch that stabilizes the boundary between sleep and wakefulness.

Lemborexant competitively blocks both OX1R and OX2R with a dissociation half-life of approximately 50 to 70 minutes, meaning its receptor occupancy falls relatively quickly once plasma concentrations decline [5]. Unlike GABA-A modulation, orexin receptor blockade does not trigger compensatory receptor upregulation at typical clinical doses. When you stop the drug, orexin signaling resumes at its prior level rather than "rebounding" above baseline. That is the key pharmacological reason abrupt cessation is tolerated.

One caveat: patients with pre-existing orexin system dysfunction (e.g., narcolepsy spectrum) should be assessed individually, since their wake drive is already compromised and removing even a mild pharmacological influence could unmask daytime symptoms.

Step-by-Step Discontinuation Protocol

The FDA prescribing information for Dayvigo does not mandate a taper [6]. A direct stop is labeled as acceptable. In clinical practice, many sleep specialists still recommend a brief step-down for patients on the 10 mg dose, particularly when treatment has lasted longer than 90 days. The protocol below reflects a consensus approach drawn from the AASM guideline and published expert commentary.

For patients on 10 mg nightly:

1. Reduce to 5 mg nightly for 7 to 14 nights.
2. Stop completely after the step-down period.
3. Monitor sleep diary metrics (sleep onset latency, WASO, total sleep time) for at least 14 nights after the last dose.

For patients on 5 mg nightly:

1. Stop the medication directly. No dose below 5 mg is commercially available, and tablet splitting is not recommended by the manufacturer.
2. Monitor sleep diary metrics for 14 nights.

Timing considerations: The 17-to-19-hour half-life means residual drug will be present the morning after the last dose. Full pharmacokinetic clearance (5 half-lives) takes approximately 4 to 5 days [6]. Any transient sleep difficulty in the first 3 nights off drug may partly reflect normal variability rather than true rebound.

Dr. Andrew Krystal, Professor of Psychiatry at UC San Francisco and principal investigator on SUNRISE-2, has stated: "The absence of rebound insomnia in the SUNRISE dataset is consistent with the pharmacology. DORAs do not produce the receptor adaptations that drive benzodiazepine withdrawal" [7].

What the SUNRISE Trials Show About Rebound Insomnia

SUNRISE-1 (N=1,006) and SUNRISE-2 (N=949) are the two registration trials that led to FDA approval in December 2019 [1][8]. Both trials included a run-out period in which patients were switched from active drug to placebo and monitored.

In SUNRISE-1, the mean change in latency to persistent sleep (LPS) on the first two nights after discontinuation did not differ significantly between the lemborexant 5 mg, 10 mg, and placebo groups [1]. WASO similarly showed no statistically significant overshoot. SUNRISE-2, a 12-month efficacy and safety study, confirmed these findings over a longer treatment period: after 6 and 12 months of nightly use, abrupt discontinuation at the end of the trial did not produce withdrawal effects or rebound insomnia on validated sleep measures [8].

A pooled analysis of adverse events in the two-night post-discontinuation window found that the most commonly reported symptom was "difficulty sleeping," occurring in 4.8% of lemborexant-treated patients versus 3.7% of placebo patients, a difference that was not statistically significant (P=0.42) [8]. Compare this to zolpidem extended-release, where rebound insomnia rates of 15% to 20% have been documented in the first 1 to 2 nights after stopping [9].

The Endocrine Society's Dr. Eve Van Cauter, who has published extensively on sleep and metabolic health, noted in a 2022 review: "Orexin antagonists represent a mechanistic departure that appears to decouple hypnotic efficacy from discontinuation risk" [10].

When Stopping May Be More Complicated

Not every patient will have a smooth discontinuation. Several clinical scenarios warrant closer monitoring or a more conservative approach.

Concurrent CNS depressant use. Patients taking benzodiazepines, opioids, or gabapentinoids alongside lemborexant have a more complex neurochemical milieu. Removing one sedating agent can unmask the dose-dependent effects of the remaining drugs. A sequential taper, addressing one agent at a time with at least 2 weeks between changes, is prudent.

Comorbid anxiety or hyperarousal disorders. Orexin blockade may be partially treating nocturnal hyperarousal in patients with generalized anxiety disorder or PTSD. Stopping lemborexant in these patients can allow the hyperarousal phenotype to reassert itself, producing what appears to be rebound insomnia but is actually the return of a pre-existing condition. Behavioral strategies (stimulus control, sleep restriction therapy) should be initiated or reinforced before discontinuation [3].

Hepatic impairment. Lemborexant is metabolized primarily by CYP3A4 [6]. Patients with moderate hepatic impairment (Child-Pugh B) have roughly doubled exposure. In these patients, the effective half-life may extend to 30 hours or more, meaning drug clearance after the last dose will take longer. A 14-night step-down period rather than 7 nights is reasonable.

Long-duration use without reassessment. The AASM guideline recommends reassessing the need for hypnotic therapy at least every 3 to 6 months [3]. Patients who have used lemborexant continuously for more than 12 months without reassessment should have a structured discontinuation trial accompanied by cognitive behavioral therapy for insomnia (CBT-I), the first-line treatment for chronic insomnia per both the AASM and the American College of Physicians [11].

Behavioral Sleep Strategies to Support Discontinuation

Stopping a sleep medication works best when paired with behavioral interventions. CBT-I has a response rate of 70% to 80% and produces durable improvements that persist years after treatment ends [11]. A 2021 meta-analysis in Annals of Internal Medicine (42 RCTs, N=5,945) confirmed that CBT-I is at least as effective as pharmacotherapy for chronic insomnia in the short term and superior in the long term [12].

The core CBT-I components most relevant to medication discontinuation are:

Sleep restriction therapy. Temporarily limit time in bed to match actual sleep time (e.g., if sleeping 5.5 hours, set a 6-hour sleep window from midnight to 6:00 AM). This builds homeostatic sleep pressure and consolidates sleep architecture.

Stimulus control. Reserve the bed for sleep only. Get out of bed after 15 to 20 minutes of wakefulness. This retrains the conditioned arousal many chronic insomnia patients develop.

Relaxation training. Progressive muscle relaxation or diaphragmatic breathing addresses the somatic hyperarousal component.

Even abbreviated CBT-I (2 to 4 sessions) delivered during the discontinuation window significantly reduces the probability of relapse back to medication use. A randomized trial published in JAMA Internal Medicine (N=188) found that brief CBT-I combined with supervised hypnotic taper produced a 55% medication-free rate at 12 months, compared to 21% with taper alone [13].

Monitoring After Discontinuation

Track three metrics using a simple sleep diary for at least 14 nights after the last dose of lemborexant:

1. Sleep onset latency (SOL): Time from lights-off to sleep onset. A sustained increase above 30 minutes on more than 3 of 7 nights suggests inadequate sleep drive or conditioned arousal.
2. Wake after sleep onset (WASO): Total minutes awake during the night. An increase above 30 minutes sustained for more than one week may indicate the need for behavioral intervention.
3. Total sleep time (TST): Most adults need 7 to 9 hours, but individual baselines vary. A decrease of more than 60 minutes from on-treatment TST that persists beyond 10 days warrants clinical review.

Expect some variability in the first 3 to 5 nights. The drug is still clearing, and anticipatory anxiety about stopping can transiently worsen sleep. This is not rebound insomnia. True rebound presents as sleep parameters that are measurably worse than pre-treatment baseline, and the SUNRISE data suggest this is uncommon with DORAs [1][8].

If sleep metrics have not returned to a stable pattern within 4 weeks, schedule a follow-up. Options at that point include restarting lemborexant at the lower dose, initiating formal CBT-I, or evaluating for an alternative sleep disorder (obstructive sleep apnea, restless legs syndrome) that may have been masked by the hypnotic.

Lemborexant vs. Other Hypnotics: Discontinuation Comparison

The discontinuation profile of lemborexant stands in contrast to several other commonly prescribed insomnia medications.

Zolpidem (Ambien) carries a well-documented rebound insomnia rate. A 2019 analysis in the Journal of Clinical Sleep Medicine found that 18.3% of patients experienced first-night rebound after stopping zolpidem extended-release, with mean sleep latency increasing by 22 minutes above baseline [9]. Suvorexant (Belsomra), the other FDA-approved DORA, shows a similarly favorable discontinuation profile to lemborexant, with no significant rebound in its key trials [14]. Eszopiclone (Lunesta) shows intermediate results: a modest rebound effect on the first discontinuation night that resolves by night 2 in most patients [15].

The Schedule IV classification of lemborexant reflects the FDA's assessment that it has low but non-zero abuse potential [6]. In human abuse liability studies, lemborexant at supratherapeutic doses (20 mg and 30 mg) produced "drug liking" scores that were statistically higher than placebo but lower than zolpidem 30 mg and suvorexant 40 mg [6]. This supports the clinical observation that psychological dependence, while possible, is less likely than with Z-drugs.

When to Restart the Medication

Not every discontinuation attempt succeeds on the first try. If insomnia returns to clinically significant levels (Insomnia Severity Index score of 15 or higher, or sleep efficiency below 75% for more than 2 consecutive weeks) after a 4-week medication-free trial, restarting lemborexant at 5 mg is appropriate [3]. This is not a failure. Chronic insomnia is a relapsing condition, and intermittent pharmacotherapy is a recognized management strategy.

Patients who cycle through multiple discontinuation attempts without sustained improvement should be referred for comprehensive sleep evaluation, including home sleep apnea testing and actigraphy, to rule out comorbid conditions that perpetuate insomnia independently of orexin-system dysfunction. The recommended first step: discuss timing and strategy with your prescriber before making any changes to your dosing schedule.